Last reviewed · How we verify
NCT03899896: FemVoc
Voice Feminisation in Transgender Women
trial in Speech Therapy in 77 participants. Completed in 5 March 2020.
5 March 2020
Quick facts
| Lead sponsor | Central Hospital, Nancy, France |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 77 |
| Start date | 28 February 2019 |
| Primary completion | 5 March 2020 |
| Estimated completion | 5 March 2020 |
| Sites | 1 location across France |
Conditions studied
- Speech Therapy — all drugs for Speech Therapy →
- Transgender Women — all drugs for Transgender Women →
- Gender Dysphoria — all drugs for Gender Dysphoria →
Sponsor
Central Hospital, Nancy, France
Who can join
18 and older, male only, with Speech Therapy or Transgender Women. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The voice is a reflection of our identity. In the case of transgender women, there may be a gap between perceived male voice and female appearance. Indeed, hormonal treatment in transgender women has no effect on the voice quality. This gap can have negative consequences on everyday life in banal situations such as telephonic contact leading to limited use of phone calls and social isolation. Differences between female and male voices seem to be socially determined and do not depend directly on sexual dimorphism of the phonatory organs. Speech therapy might thus be indicated as a vocal support for transgender women. Only few studies have examined the impact of perceived voice on the quality of life of transgender women.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03899896
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Speech Therapy
Currently open trials in the same condition.
- NCT05900180 — Pediatric Speech Therapy Session Frequency and Speech Outcomes · NA · active not recruiting
- NCT05635760 — Parent-implemented Social Communication Treatment in Autism · NA · active not recruiting
- NCT06105099 — Effect of Performance-specific Cleft Speech Intervention and Long-term Learning in Children With a Cleft Palate · NA · recruiting
- NCT05455411 — Parent-implemented Social Communication Treatment in Preschool Children With Autism Spectrum Disorder · NA · active not recruiting
Other Central Hospital, Nancy, France trials
Trials by the same sponsor.
- NCT06452290 — PET Biomarker Study for Antidepressant Response Prediction in Major Depressive Disorder · NA · not yet recruiting
- NCT07518498 — Hypnosis During Mechanical Ventilation Weaning · NA · not yet recruiting
- NCT07471334 — Prospective Study of Postictal Psychotic Symptoms Occuring After Video-EEG Monitoring in Focal Epilepsies · NA · not yet recruiting
- NCT07414667 — Primary Sjögren's Syndrome: Impact of Quantitative Anti-Ro52 Antibody Analysis on Patient Prognosis and Stratification ( · not yet recruiting
- NCT07415759 — Imaging of Electrical Properties by MRI: Investigation of Age-Related Changes · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03899896 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Central Hospital, Nancy, France
- Last refreshed: 25 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03899896.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing